Acceleron is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s remarkable capacity for cellular growth and repair.
Our strategy is to develop medicines that selectively target multiple ligands (proteins) in the TGF-beta superfamily, which play critical roles in the development of serious diseases. Our deep scientific leadership in this area of biology has enabled us to focus our research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, we are developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. We are now planning multiple Phase 3 trials with the potential to support the long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease.
We are also investigating the potential of our early-stage pulmonary candidate, ACE-1334, which we plan to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) during 2021.
In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. With our partner, we are co-promoting REBLOZYL in the United States and are developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.